- Home
- SUPN vs BHC Comparison
SUPN vs BHC Comparison
Compare SUPN & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- BHC
- Stock Information
- Founded
- SUPN 2005
- BHC N/A
- Country
- SUPN United States
- BHC Canada
- Employees
- SUPN N/A
- BHC N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- BHC Health Care
- Exchange
- SUPN Nasdaq
- BHC Nasdaq
- Market Cap
- SUPN 1.9B
- BHC 1.7B
- IPO Year
- SUPN 2012
- BHC N/A
- Fundamental
- Price
- SUPN $32.28
- BHC $6.18
- Analyst Decision
- SUPN Hold
- BHC Hold
- Analyst Count
- SUPN 2
- BHC 5
- Target Price
- SUPN $36.00
- BHC $7.20
- AVG Volume (30 Days)
- SUPN 529.3K
- BHC 2.5M
- Earning Date
- SUPN 08-05-2025
- BHC 07-31-2025
- Dividend Yield
- SUPN N/A
- BHC N/A
- EPS Growth
- SUPN N/A
- BHC N/A
- EPS
- SUPN 1.11
- BHC N/A
- Revenue
- SUPN $667,997,000.00
- BHC $9,731,000,000.00
- Revenue This Year
- SUPN N/A
- BHC $3.71
- Revenue Next Year
- SUPN $12.02
- BHC $5.03
- P/E Ratio
- SUPN $29.32
- BHC N/A
- Revenue Growth
- SUPN 11.82
- BHC 8.53
- 52 Week Low
- SUPN $25.55
- BHC $3.96
- 52 Week High
- SUPN $40.28
- BHC $9.85
- Technical
- Relative Strength Index (RSI)
- SUPN 48.28
- BHC 73.53
- Support Level
- SUPN $31.56
- BHC $4.41
- Resistance Level
- SUPN $33.15
- BHC $6.31
- Average True Range (ATR)
- SUPN 0.92
- BHC 0.27
- MACD
- SUPN -0.03
- BHC 0.17
- Stochastic Oscillator
- SUPN 40.34
- BHC 92.89
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.